Stockwinners Market Radar for July 21, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:20 EDT Booz Allen pays $377.5M to settle U.S. investigation over charges - Booz Allen Hamilton Holding said it entered into a settlement agreement with the United States of America, acting through the United States Department of Justice and on behalf of the Defense Contract Management Agency, to resolve the previously disclosed civil investigation related to certain elements of the company's cost accounting and indirect cost charging practices from April 1, 2011 through March 31, 2021. Under the terms of the agreement, Booz Allen has agreed to pay to the United States $377.5M, which the company expects to pay with cash on hand and by drawing on its revolving credit facility. The company had previously recorded a $350M reserve relating to the investigation and had previously disclosed that it believed the range of reasonably possible loss in connection with the investigation to be between $350M and $378M Upon the United States' receipt of the amount, the United States will release the company from any civil or administrative monetary claims for the covered conduct under the civil False Claims Act. Booz Allen said it entered into the agreement "to avoid the delay, uncertainty and expense of protracted litigation." The settlement agreement contains no admission of liability by the company.

18:05 EDT Verint CEO Bodner sells 29,230 common shares - In a regulatory filing, Verint Systems chairman and CEO Dan Bodner disclosed the sale of 29,230 common shares of the company on July 20 at a price of $38.33 per share.

17:58 EDT Boeing awarded $393.09M Army contract modification - Boeing was awarded a $393.09M modification to a contract for Apache AH-64E aircraft, supporting services, and equipment. Work will be performed in Mesa, Arizona, with an estimated completion date of Dec. 31, 2027. FY23 aircraft procurement, Army funds and Foreign Military Sales funds in the amount of $393,09M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:04 EDT Gilead to discontinue Phase 3 ENHANCE study of magrolimab plus azacitidine - Gilead Sciences announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes, MDS, has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing trials in solid tumors and two pivotal trials: ENHANCE-2 study in acute myeloid leukemia, AML, with TP53 mutations and ENHANCE-3 in first-line, unfit AML. "The health and well-being of patients are our top priorities and while this is disappointing news it confirms the challenges of treating HR-MDS, where no new class of treatments have been approved in nearly 20 years," said Merdad Parsey, Chief Medical Officer, Gilead Sciences. "Gilead is deeply grateful to the patients, families, investigators, and the advocacy community who contributed to this research as we learn more about magrolimab and explore its potential in treating other cancers." Gilead is working with study investigators on appropriate next steps for patients enrolled in the ENHANCE study. Data will be submitted for presentation at an upcoming medical meeting.

16:53 EDT Bank of America exec Athanasia sells 77,806 per share - In a regulatory filing, Bank of America president of Regional Banking Dean Athanasia disclosed the sale of 77,806 common shares of the company on July 20 at a price of $31.485 per share.

16:33 EDT Horizon Therapeutics says daxdilimab trial did not show statistical significance - Horizon Therapeutics announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which was the proportion of patients to achieve a British Isles Lupus Assessment Group, or BILAG, 2004 Index-based Combined Lupus Assessment, or BICLA, response and an oral glucocorticoid, or OGC, dose of less than or equal to 7.5 mg/day, which represented a reduction from the Baseline OGC dose at 48 weeks. BICLA is a composite measure indicating low SLE disease activity. Numerical differences were seen in other endpoints. No safety concerns were reported.

16:31 EDT Becton Dickinson receives FDA 510k clearance for updated BD Alaris system - BD announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration, which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit, large volume pumps, syringe pumps, patient-controlled analgesia pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record systems. "The 510(k) clearance of the updated BD Alaris(TM) Infusion System has been the number one priority for our teams who have been steadfast in their efforts to achieve this milestone, consistent with our commitment to quality," said Tom Polen, chairman, CEO and president of BD. "We are deeply committed to ensuring clinicians can continue to rely on our market leading system to meet today's most critical infusion needs. The features and enhancements incorporated into the updated BD Alaris Infusion System and subject to this clearance reinforce our advancements in smart, connected care, which deliver greater benefit to clinicians and patients and help improve health care system efficiency through better care coordination and utilization of actionable information."

16:17 EDT Knightscope receives letter of compliance from Nasdaq - Knightscope announced that the company has regained compliance with The Nasdaq Global Market Listing Rule 5450(b)(2)(A). On March 29, 2023, Staff notified the company that it had failed to maintain a minimum market value of listed securities of $50,000,000 over the previous 30 consecutive business days as required by the Rule. Since then, Staff has determined that for the last 10 consecutive business days, from July 7, through July 20, 2023, the company's market value of listed securities has been $50,000,000 or greater and this matter is now closed.

16:09 EDT Atento trading halted, news pending

16:02 EDT ViewRay announces commencement of Nasdaq delisting proceedings - ViewRay announced that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC. Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common stock will be suspended at the opening of business on July 26, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. Once the delisting from Nasdaq takes effect, the Company's common stock is expected to begin trading on the over-the counter markets. On the OTC market, shares of the Company's common stock, which previously traded on Nasdaq under the symbol "VRAY", are expected to trade under the symbol "VRAYQ". The transition to the OTC markets will not affect the Company's intention to continue to operate in the normal course while in chapter 11. The Company will remain subject to the public reporting requirements of the SEC following the transfer.

15:06 EDT Pfizer announces post-tornado relief plans for Rocky Mount facility - Pfizer announced the company's immediate efforts to provide relief and repair the damage caused to its manufacturing facility in Rocky Mount, North Carolina after a violent tornado swept through the town on Wednesday, July 19. "All 3,200 local Pfizer colleagues reporting to this manufacturing site are safe and accounted for after excellent implementation of the site's long-standing evacuation plan. Crews are working around-the-clock to restore power, assess the structural integrity of the building and move finished medicines to nearby sites for storage. Pfizer also announced a donation to the American Red Cross North Carolina Chapter and United Way Tar River Region to support the relief and recovery needs. Additionally, the Pfizer Foundation will match employee donations to these organizations. The site is closed while the damage is assessed. Pfizer is committed to rapidly restoring full function to the site, which plays a critical role in the U.S. healthcare system. This effort is in close partnership with the U.S. Food and Drug Administration Commissioner Robert Califf, North Carolina Governor Roy Cooper as well as other state, local and federal officials. Most of the damage was caused to the warehouse facility, which stores raw materials, packaging supplies, and finished medicines awaiting release by quality assurance. Pfizer is working diligently to move product to other nearby sites for storage and to identify sources to replace damaged raw materials and supplies. Pfizer is also exploring alternative manufacturing locations for production across our significant manufacturing presence in the U.S. and internationally and across the company's partner network. After an initial assessment, there does not appear to be any major damage to the medicine production areas. Since 1968, the Rocky Mount facility has been a key producer for sterile injectables. Currently, it is responsible for manufacturing nearly 25% of all Pfizer's sterile injectables - including anesthesia, analgesia, therapeutics, anti-infectives and neuromuscular blockers - which is nearly 8% of all the sterile injectables used in U.S. hospitals. The site is one of 10 Pfizer manufacturing sites located in the United States," the company stated. "Clearly nature is strong. So too is ingenuity and the human spirit. A great deal of work needs to be done, but I assure everyone, most importantly the people of the Rocky Mount community, that we will put Pfizer's full power behind this effort. We will work in lockstep with our partners and local authorities to restore and rebuild the site and the community," said Dr. Albert Bourla, Chairman and CEO of Pfizer.

14:35 EDT Pfizer receives 'positive' CHMP opinion for alopecia areata treatment - Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for LITFULO, an oral treatment, recommending marketing authorization of once-daily 50 mg for individuals 12 years of age and older with severe alopecia areata. The European Commission, which authorizes central marketing approvals in the European Union (EU), will take a legally binding decision based on the CHMP recommendation and is expected to make a final decision in the coming months. If granted, the centralized marketing authorization of LITFULO would be valid in all 27 EU member states, as well as in Iceland, Liechtenstein, and Norway. LITFULO, if approved, would be the only treatment authorized for patients as young as 12 years of age with severe alopecia areata in this market. "Alopecia areata is an autoimmune disease and the burden of hair loss can negatively impact patients' day-to-day lives," said Aida Habtezion, Senior Vice President, Chief Medical Officer and Head of Worldwide Medical and Safety, Pfizer Inc. "This positive CHMP recommendation for LITFULO brings us one step closer to providing a once-daily treatment for patients as young as 12 years of age in the EU who are living with the challenges of severe alopecia areata."

14:28 EDT Corteva increases quarterly dividend 7% to 16c per share - Corteva announced its board of directors has authorized a common stock dividend of 16c per share, representing an annualized increase of approximately 7% over the company's previous quarterly dividend and payable September 15 to the company's shareholders of record on September 1. "This is the Corteva's third dividend increase since its 2019 spin-off and a result of the company's firm focus on driving margin expansion and sustainable long-term growth through industry-leading innovation, high-touch customer engagement, together with disciplined operational execution. This announcement reflects the company's continued focus on returning capital to shareholders," Corteva stated.

13:03 EDT Baker Hughes reports U.S. rig count down 6 to 669 rigs - Baker Hughes reports the U.S. rig count is down 6 from last week to 669 rigs, with oil rigs down 7 to 530, gas rigs down 2 to 131 and miscellaneous rigs up 3 to 8. The U.S. rig count is down 89 rigs from last year's count of 758, with oil rigs down 69, gas rigs down 24 and miscellaneous up 4. The U.S. offshore rig count is unchanged at 18, up 2 year-over-year.

12:23 EDT Amazon to open satellite-processing facility at Kennedy Space Center - Amazon said that Project Kuiper is moving one step closer to deploying its full satellite constellation, with construction underway on a new satellite-processing facility at Space Florida's Launch and Landing Facility at Kennedy Space Center. The facility is the latest long-term investment in Project Kuiper, a low Earth orbit satellite network that will provide fast, affordable broadband to unserved and underserved communities around the world. The space will be used to prepare and integrate Kuiper satellites with rockets from Blue Origin and United Launch Alliance ahead of launches. It stems from an expected partnership with Space Florida's Spaceport Improvement Program. Project Kuiper will begin satellite production at a state-of-the-art manufacturing facility in Kirkland, Washington, by the end of this year. The new satellite-processing facility in Florida will be used to receive those satellite shipments, conduct final preparations ahead of launches, connect satellites to custom dispensers from Beyond Gravity, and integrate the loaded dispensers with launch vehicles. The 100,000-square-foot facility features a 100-foot tall high bay clean room to allow room for the payload fairing of new heavy-lift rockets like Blue Origin's New Glenn and ULA's Vulcan Centaur. Amazon is investing $120M in new construction and high-value equipment for the facility, and creating up to 50 new jobs on the Space Coast. These Project Kuiper facilities are critical to Amazon's commitment to spur innovation; design and develop prototype and production satellites; and prepare our satellites for commercial deployment. Reference Link

12:00 EDT Hilltop Holdings falls -10.6% - Hilltop Holdings is down -10.6%, or -$3.51 to $29.67.

12:00 EDT Five Point Holdings rises 11.8% - Five Point Holdings is up 11.8%, or 37c to $3.50.

12:00 EDT ServisFirst rises 17.3% - ServisFirst is up 17.3%, or $8.37 to $56.81.

11:21 EDT Thorne HealthTech trading resumes

10:38 EDT Diversified Healthcare recommends shareholders vote for Office Properties merger - Diversified Healthcare Trust (DHC) announced the filing of definitive proxy materials with the U.S. Securities and Exchange Commission in connection with DHC's pending merger with Office Properties Income Trust (OPI). The DHC Board of Trustees unanimously recommends that shareholders vote "FOR" the proposal to approve the merger agreement with OPI. The DHC Board believes that the merger is the best available opportunity for long term value for common shareholders. A Special Meeting of Shareholders is scheduled on Wednesday, August 30, 2023, at 11:00 a.m. Eastern Time. DHC shareholders of record as of the close of business on June 16, 2023, are eligible to vote. Subject to shareholder approval and satisfaction of all other closing conditions, the merger is expected to close during the third quarter of 2023.

10:03 EDT Digital World Acquisition Corp trading resumes

10:00 EDT Sensient falls -8.6% - Sensient is down -8.6%, or -$5.96 to $63.41.

10:00 EDT Posco rises 9.8% - Posco is up 9.8%, or $9.53 to $106.40.

10:00 EDT ServisFirst rises 15.4% - ServisFirst is up 15.4%, or $7.47 to $55.91.

09:52 EDT Sirius XM trading resumes

09:47 EDT Sirius XM trading halted, volatility trading pause

09:47 EDT Hilltop Holdings falls -7.3% - Hilltop Holdings is down -7.3%, or -$2.43 to $30.75.

09:47 EDT Interpublic Group falls -9.0% - Interpublic Group is down -9.0%, or -$3.42 to $34.50.

09:47 EDT Emergent BioSolutions rises 7.9% - Emergent BioSolutions is up 7.9%, or 56c to $7.62.

09:46 EDT ReNew Energy Global signs MoUs for INR 640B for green energy projects - ReNew Energy Global has signed Memorandums of Understanding worth INR 640B with Power Finance Corporation and Rural Electrification Corporation for its green energy projects. According to the MoUs signed with the lenders at the Clean Energy Ministerial meeting in Goa, ReNew will receive INR 320B each from PFC and REC for financing its current and upcoming energy transition projects. The MoUs support the ongoing efforts to further the clean energy transition under India's G20 presidency. The company will utilize the funds for new projects including solar, wind, hybrid, energy storage, solar modules and cells manufacturing and green hydrogen.

09:45 EDT Evelo Biosciences trading resumes

09:40 EDT Evelo Biosciences trading halted, volatility trading pause

09:33 EDT CHMP recommends Roche's Evrysdi for babies under two months old with SMA - Roche announced that the EU Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the extension of the Evrysdi European Union marketing authorization, which would include infants with genetically confirmed diagnosis of spinal muscular atrophy, or SMA, Type 1, Type 2 or Type 3 or with one to four SMN2 copies, including from birth to below two months. "The recommendation is based on an interim analysis from the ongoing RAINBOWFISH trial in pre-symptomatic babies with Type 1 SMA from birth to six weeks. In SMA, early treatment is critical to counteract ongoing and irreversible loss of motor neurons. A final decision regarding the approval is expected from the European Commission later this year," the company stated.

09:32 EDT Priveterra Acquisition Corp trading halted, volatility trading pause

09:22 EDT ATN International provides update on legacy lead-sheathed cables - In response to recent media reporting in the United States, ATN International completed a preliminary assessment of its communications network regarding the presence of legacy lead-sheath telecom cables in its network. ATN estimates that in the United States and its territories, its network contains less than 10 miles of lead-sheathed copper cables and outside of the United States just over 20 miles of lead-sheathed copper cables, substantially all of which are within conduit buried underground and to its knowledge, are not located underwater. ATN continues to prioritize the safety of its employees, customers, and communities where it operates.

09:11 EDT Incannex submits IND application to FDA for IHL-42X in obstructive sleep - Incannex Healthcare has submitted an Investigational New Drug application to the US Food and Drug Administration for IHL-42X for treatment of obstructive sleep apnoea. The IND dossier compiled by the Incannex team includes comprehensive modules on the safety and efficacy of IHL-42X and its component active pharmaceutical ingredients. It also includes detailed information on the development, manufacturing, quality and stability of the IHL-42X drug product, as well as the clinical protocol and investigator information for the Phase 2/3 IND opening clinical trial. The modules of the IND are: Module 1 - Administrative Information and Prescribing Information; Module 2 - Nonclinical/Clinical Overviews and Summaries; Module 3 - Quality data; Module 4 - Nonclinical Study Reports and Key Literature References; Module 5 - Clinical Study Reports, Clinical Protocol and Investigator Information. The IND application details the clinical trial protocol for the IND opening clinical trial, which is a multi-site phase 2/3 clinical trial investigating IHL-42X for the treatment of Obstructive Sleep Apnoea. This pivotal trial will assess IHL-42X at the best performing two doses from the successful phase 2 proof-of-concept clinical trial, in patients with OSA who are intolerant, non-compliant, or naive to positive airway pressure, over a 52-week treatment period. Participants will receive one of IHL-42X, dronabinol, acetazolamide or placebo for the entirety of the trial. All participants will complete daily surveys on their sleep quality, attend monthly clinic visits to assess functional outcomes of sleep, cognitive function and other measures of safety and efficacy. Every three months, overnight polysomnography will be conducted to determine the effect of treatment on the patients' Apnoea Hypopnea Index score along with a range of other sleep parameters. All drug treatments will be compared to placebo.

09:04 EDT Abercrombie & Fitch opens Fifth Avenue NYC storefront - Abercrombie & Fitch announced the opening of its new 5th Avenue store today, July 21. Located at 668 Fifth Avenue, between 52nd and 53rd Streets, the store offers Abercrombie & Fitch's women's and men's collections as well as dedicated shop-in-shop spaces for both its kids' brand, abercrombie kids, and its adult activewear franchise, YPB.

09:03 EDT CPS Technologies appoints Brian Mackey as president, CEO - CPS Technologies announced that Brian Mackey has been appointed president and CEO of CPS effective August 14, 2023. His selection comes at the conclusion of an exhaustive search for an appropriate individual following Michael McCormack's resignation in April, after which the Company's CFO, Chuck Griffith, has served as acting president. Before joining CPS, Mr. Mackey served for five years as the CEO of Engi-Mat Co.

09:02 EDT Tompkins Financial announces new 400,000 share stock repurchase plan - Tompkins Financial announced that its board of directors has authorized a new stock repurchase program of up to 400,000 shares of the company's outstanding common stock, par value 10c per share. This program replaces the company's existing 400,000 share repurchase program announced on October 22, 2021.

08:39 EDT Safe & Green regains compliance with Nasdaq - Safe & Green announced that the company received notice from Nasdaq on July 20, indicating that it has regained compliance with the minimum bid price requirement under Nasdaq Rules 5550.

08:33 EDT Camber Energy, Viking Energy announce shareholder approval of merger - Camber Energy and Viking Energy Group announced that the shareholders of each of Camber and Viking approved by the requisite voting thresholds at special meetings held separately by each company on July 20, 2023, the various proposals relating to the adoption and approval of the Agreement and Plan of Merger between Camber and Viking dated February 15, 2021, as amended on April 18, 2023 and the transactions contemplated by the Merger Agreement, including a wholly owned subsidiary of Camber merging with and into Viking, with Viking surviving the Merger as a wholly owned subsidiary of Camber and Camber remaining the sole publicly-traded entity. Camber and Viking anticipate that the Merger will be completed on or about August 1, 2023, subject to the satisfaction of required closing conditions.

08:32 EDT Cansortium appoints John Mazarakis to board of directors - Cansortium has appointed John Mazarakis to its board of directors effective July 17, 2023. Mr. Mazarakis replaces John McKimm on the Board, who resigned from the Board effective June 30, 2023. Mazarakis brings over 20 years of entrepreneurial, operational, and managerial experience to Cansortium. Over the last two decades, he has launched successful ventures in real estate, retail, hospitality and personal fitness.

08:19 EDT Trulieve Cannabis appoints Ryan Blust as interim CFO - Trulieve Cannabis announced the appointment of Ryan Blust, the Company's Vice President, Finance, as its interim Chief Financial Officer, CFO, and the departure of Tim Mullany as Chief Financial Officer for personal reasons, each effective July 20, 2023. The Company has also retained the services of an executive recruitment firm to commence a search for a new chief financial officer. Blust has over 18 years of accounting and finance experience. He joined Trulieve in September 2018, and has previously served as interim CFO for the Company.

08:11 EDT Biotricity regains Nasdaq listing compliance - Biotricity has received notice from The NASDAQ Stock Market on July 18, 2023 informing Biotricity that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

08:10 EDT Fresh Tracks enters amendment to asset purchase agreement with Botanix - Fresh Tracks Therapeutics has entered into an amendment to its Asset Purchase Agreement with Botanix Pharmaceuticals and its subsidiary, Botanix SB to sell its rights to future event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB for $8.25M. In May 2022, pursuant to the Asset Purchase Agreement, Botanix acquired from Fresh Tracks all assets primarily related to sofpironium bromide. Under the terms of the APA Amendment, Botanix will pay $8.25M in cash in lieu of all remaining amounts potentially payable by Botanix to the Company, $6.6M of which is payable to the Company and the remaining $1.65M is payable to the Company's former licensor.

08:07 EDT Freshpet appoints Dave West to board of directors - Freshpet announced that David West has been appointed to the Company's Board of Directors, effective July 21, 2023. Mr. West will serve on the Board's Audit Committee. West's experience includes serving as CEO of Big Heart Pet Brands and as CEO, President and director of The Hershey Company. West will stand for election as a Class III director at the Company's 2023 annual meeting of shareholders and replaces Charles Norris, who is retiring from the Board immediately and not standing for election in accordance with the Company's mandatory retirement policy. In accordance with the previously announced Chair transition, current director and Chair of the Board's Nominating, Governance and Sustainability Committee Walt George has assumed the role of Chair of the Board, effective immediately. With the addition of Mr. West and retirement of Mr. Norris, the Board is now comprised of 10 directors, nine of whom are independent.

08:04 EDT Wearable Devices debuts Mudra Licensing program - Wearable Devices announced the launch of its licensing program for the B2B market. The program provides for a royalty based license agreement where original equipment manufacturers will have the right to customize a reference design version of the Company's Mudra gesture technology to meet the specific needs of their business. The company said, "The Company's proprietary technology is at the forefront of gesture recognition, using AI-based touchless sensing wearables to control devices with hand gestures. With the launch of the Mudra licensing program, Wearable Devices is positioned to significantly expand its addressable market by enabling businesses to develop their own co-branded touchless control products."

08:00 EDT Mirati announces EMA's CHMP issued negative opinion on MAA for KRAZATI - Mirati Therapeutics announced the European Medicine Agency's, EMA, Committee for Medicinal Products for Human Use, CHMP, issued a negative opinion on the Conditional Marketing Authorisation Application, MAA, for KRAZATI for treatment of patients with KRASG12C -mutated advanced non-small cell lung cancer, NSCLC. Mirati disagrees with the opinion and intends to request a formal re-examination. CHMP states that KRAZATI has a positive risk-benefit profile, however, does not fulfill certain requirements for a Conditional Marketing Authorisation. Mirati believes KRAZATI addresses the Conditional Marketing Authorisation requirements despite there being a currently conditionally approved KRASG12C inhibitor and that KRAZATI possesses a differentiated clinical profile. "We remain steadfast in our belief in the potential of adagrasib to provide hope for patients in the European Union," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "We will continue to work closely with the EMA and the CHMP to bring adagrasib to eligible patients. We are committed to delivering therapeutic options for patients living with KRASG12C-mutated NSCLC in the EU, as we have in the United States following the Accelerated Approval of KRAZATI in December 2022." This decision will have no impact on any of Mirati's clinical trials.

07:55 EDT Merck announces CHMP opinion recommending approval of gefapixant - Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough. The CHMP's recommendation will now be reviewed by the European Commission for marketing authorization in the European Union and a final decision is expected later this year.

07:51 EDT BeiGene announces CHMP opinion recommending approval for tislelizumab - BeiGene announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued an opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.

07:48 EDT Lifeist Wellness closes on Zest acquisition - Lifeist Wellness has acquired 100% of 1000501971 Ontario for $3,411,707.90 in an all-stock transaction. The company said, "The Acquisition will enhance the competitive position of Lifeist and CannMart in the cannabis industry by adding a complementary portfolio of hydrocarbon vape, infused pre-rolls and flower SKUs to the current product assortment of cannabis concentrates offered by in-house brand Roilty. CannMart, Lifeist's B2B wholesale distribution business facilitating recreational cannabis sales within Canada, will continue to develop and expand the Zest brand's already strong store penetration, and broaden the scope and scale of cannabis category offerings across Canada. The Acquisition has strengthened Lifeist's ability to serve the various and evolving needs of customers across the marketplace today and into the future." The Acquisition was completed pursuant to the terms of an amended and restated share purchase agreement, dated July 19, 2023, which amended and restated the Share Purchase Agreement. Pursuant to the terms of the Amended Acquisition Agreement, the Company acquired 100% of the issued and outstanding shares of Zest from Zest Cannabis Inc. and issued the Share Consideration to 13735346 Canada Inc. and 1000496959 Ontario. The Company issued the aggregate consideration of 68,234,158 common shares of the Company valued at $3.4 million, on the basis of a deemed price of $0.05 per Common Share and issued at a premium to market. The total Consideration Shares for the Acquisition includes: 30,734,158 Common Shares at a price of $0.05 per Common Share, and 37,500,000 Common Shares at a price of $0.05 per Common Share, to be held in escrow and released over a period of nine months in accordance with certain milestones pursuant to the terms and conditions of an escrow agreement. As a condition of the Acquisition, each Seller's Shareholder will enter into a support and voting agreement with respect to the Consideration Shares received by the Seller's Shareholders in connection with the Acquisition. Pursuant to the Voting Agreement, the Company will provide written notice to each Seller's Shareholder recommending how the Considerations Shares should be voted. The Seller's Shareholders have the right to abstain from voting. The Voting Agreement will automatically terminate two years after the date of the closing of the Acquisition.

07:24 EDT RedHill Biopharma announces U.S. government funding for Opaganib development - RedHill Biopharma announced that opaganib has been awarded a further $1.7M in U.S. Government funding, via a Small Business Innovation Research grant to the company's development partner, Apogee Biotechnology Corporation. This SBIR grant will support research to further the development of opaganib as a medical countermeasure for gastrointestinal acute radiation syndrome. This grant is in addition and complementary to the multimillion dollar-valued U.S. Government Radiation and Nuclear Countermeasures Program product pipeline development contract awarded to opaganib following its selection by the RNCP for ARS development.

07:13 EDT Theratechnologies director Gary Littlejohn resigns - Theratechnologies announced that Mr. Gary Littlejohn has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. Consistent with past practices, the Board of Directors of the Company will assess whether it will appoint a new member to fill this vacancy before the next annual meeting of shareholders.

07:12 EDT Renalytix enters Middle East distribution agreement with Vector Pharma - Renalytix announces opening the commercial availability of kidneyintelX.dkd testing in Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and United Arab Emirates through a distribution agreement with Vector Pharma. Following the recent announcement of FDA marketing authorization for kidneyintelX.dkd, Renalytix will take advantage of select opportunities to expand testing services outside the US market with qualified distribution partners. In the six markets of the Gulf Cooperation Council, the International Diabetes Federation has reported high prevalence rates of diabetes, with more than 20% of the population being diabetic and more than 15% being pre-diabetic in most GCC countries. These are among the highest reported incidence rates for diabetes globally.

06:58 EDT Dollar General announces back-to-school savings initiatives - This back-to-school season, Dollar General is committed to providing quality and affordable school essentials that students, parents and teachers are proud to purchase and use. With over 19,000 locations in 47 states, Dollar General offers a convenient shopping experience with special discounts and product selections that help start the school year off right. This includes: Teacher Discounts Now through September 15, Dollar General is offering a 30 percent discount on school supplies and housewares for verified teachers. To register and complete the verification process and find a little inspiration for the year ahead, visit DG's Teacher's Central to shop for supplies, discover classroom craft activities and stay organized. Product Favorites with Budget-Friendly Savings: Customers can increase their savings with a DG Digital Coupon offering $2 off any qualifying school supplies purchase of $10 or more, available select weeks in July, August and September. This and more offers are available through DG Digital Coupons online and in the myDG App where customers may load coupons and rewards on an easy-to-use platform and redeem them at checkout. In addition to the Dollar General weekly savings ads, customers can scan products in-store for pricing and to surface available coupons and deals. Dollar General offers some of the most trusted national brands for back-to-school shoppers including Crayola, BIC, Elmer's and more as well as several private brands like iMagine and Office Hub that offer a 100 percent satisfaction guarantee. Students headed to campus this year can purchase items that are perfect for maximizing small spaces while personalizing them with on-trend decor and essentials.

06:55 EDT SLB CEO expects 2H23 FCF generation to be 'visibly higher' than 1H - CEO Olivier Le Peuch said, ""Second-quarter cash flow from operations vastly improved to $1.61 billion-$1.28 billion higher sequentially-and free cash flow was $986 million. Contributing to this very strong cash flow performance were higher earnings, robust receivable collections, improved inventory turnover, and continued capex discipline. We expect free cash flow generation in the second half of the year to be visibly higher than the first half, firmly positioning us to outperform last year's free cash flow."

06:48 EDT Chase Corporation to be acquired by KKR for $127.50 per share in cash

06:34 EDT Safran to acquire Collins Aerospace actuation, flight control business - Safran (SAFRY) announces the contemplated acquisition of Collins Aerospace's (RTX) high-technology actuation and flight control activities, which are mission critical for commercial & military aircraft and helicopters. The business has around 3,700 employees across eight facilities in Europe and in Asia, and also benefits from MRO and engineering capabilities. It is expected to generate sales of approximately $1.5B and an EBITDA of $130M in 2024. The transaction is expected to generate approximately $50M of annual pre-tax run-rate cost synergies, which would be progressively implemented from 2025 to 2028. Such synergies would come from economies of scale in procurement, R&D complementarity, internalization of sourcing and production flows. In addition, commercial synergies would be obtained through integrated offerings and a diversification of customers and geographic mix. Commercial synergies would continue post 2028 with run-rate achieved on next-generation aircraft by the middle of the next decade. The enterprise value of $1.8B would represent a multiple of approximately 14x pre-cost synergies and 10x post run-rate cost synergies based on 2024E EBITDA, with an expected IRR and ROCE 2028E of the transaction exceeding the Group's WACC and with an accretive impact on Safran earnings per share from year one. As part of the contemplated acquisition, long-term supply agreements would be secured between Safran and Collins. The transaction is expected to be fully financed with available cash, with a limited impact on the group's net leverage and a reiterated commitment to the group's investment grade rating. The contemplated transaction is subject to the information and consultation procedure with the relevant employee representative bodies of Collins and Safran, as well as the customary regulatory approvals and closing conditions. Closing is expected to take place in the course of H2 2024.

06:13 EDT Ferroglobe announces notice of redemption of $150M of senior notes - Ferroglobe announced that its subsidiary issuers of the 9.375% Senior Secured Notes due 2025 have given a notice of partial redemption of such Notes at 102.34375% of the principal amount plus accrued interest. The issuers elect to redeem an aggregate principal amount of $150 million of the Notes plus accrued and unpaid interest of approximately $14 million, assuming the expected redemption date of July 31, 2023. The Notes are expected to be redeemed with cash on the balance sheet.

06:10 EDT Lottery.com appoints Robert Stubblefield as CFO - On July 14, 2023, the Board of Directors appointed Robert Stubblefield as CFO of the Company, effective immediately. Mr. Stubblefield brings with him extensive financial expertise, having recently served as the CFO of Demeta, Inc. and Regnum.

06:08 EDT Lottery.com enters funding agreement with United Capital Investments London - Lottery.com announces that United Capital Investments London has agreed to enter into a funding agreement with the Company. The terms and conditions of the funding agreement with UCIL will be announced after the definitive agreement is finalized.

05:06 EDT RTX opens $14M expansion of additive manufacturing center in Iowa - Collins Aerospace, an RTX business, celebrated the opening of a $14M expansion of its additive manufacturing center in West Des Moines, Iowa. The 9,000-square-foot addition provides space for the site to house several new state-of-the-art 3D metal printers. The first printer installed has eight times the build volume of the facility's existing printers, significantly increasing the center's additive manufacturing capabilities.